BlackRock Inc. Boosts Position in Gilead Sciences, Inc. (GILD)

BlackRock Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 105,236,053 shares of the biopharmaceutical company’s stock after buying an additional 1,438,806 shares during the period. BlackRock Inc. owned approximately 8.07% of Gilead Sciences worth $7,933,746,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Bank of New York Mellon Corp boosted its holdings in Gilead Sciences by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock worth $2,188,095,000 after purchasing an additional 446,263 shares during the period. Parnassus Investments CA boosted its holdings in shares of Gilead Sciences by 2.5% during the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after acquiring an additional 464,609 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after acquiring an additional 379,867 shares during the period. Capital International Investors lifted its holdings in Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after purchasing an additional 5,205,983 shares during the period. Finally, Sanders Capital LLC lifted its holdings in Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after purchasing an additional 5,026,015 shares during the period. Hedge funds and other institutional investors own 77.72% of the company’s stock.

Gilead Sciences opened at $67.38 on Friday, MarketBeat Ratings reports. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The stock has a market cap of $88.64 billion, a price-to-earnings ratio of 7.87, a price-to-earnings-growth ratio of -5.93 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period last year, the firm earned $2.23 EPS. The company’s revenue was down 21.8% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 5.75 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.38%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $80.93, for a total transaction of $472,064.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 226,667 shares of company stock worth $17,060,854. Company insiders own 1.30% of the company’s stock.

Several equities research analysts recently weighed in on GILD shares. Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Thursday, April 19th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Barclays dropped their price target on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Finally, Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $88.80 to $76.00 in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $88.14.

Gilead Sciences Profile

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply